Clinical trial · Interventional
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib Tosilate Tablets or Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT06233994CI-TRIAL-00073456unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized, open-label study to evaluate the safety and efficacy of ZG005 in combination with Donafenib or Bevacizumab in patients with advanced hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Biological | Bevacizumab | ALIAS |
| Donafenib Tosilate Tablets | Drug | — | UNRESOLVED |
| ZG005 Powder for Injection | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ZG005+Donafenib
- description
- Participants will receive ZG005 plus Donafenib until unacceptable toxicity or loss of clinical benefit.
- interventionNames
- Biological: ZG005 Powder for Injection
- Drug: Donafenib Tosilate Tablets
- type
- EXPERIMENTAL
- label
- ZG005+Bevacizumab
- description
- Participants will receive ZG005 plus bevacizumab until unacceptable toxicity or loss of clinical benefit.
- interventionNames
- Biological: ZG005 Powder for Injection
- Biological: Bevacizumab
Primary outcomes (2)
- measure
- Objective Response Rate (ORR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female ≥18 years of age. * Fully understand the study and voluntarily sign the informed consent form. * Histologically or cytologically confirmed diagnosis of metastatic or unresectable hepatocellular carcinoma (HCC). * Life expectancy \>= 3 months. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Exclusion Criteria: * Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. * Patients were deemed unsuitable for participating in the studyl by the investigator for any reasons.
References
Publications (0)
Data not yet available
No reference posted for this study.